Atherosclerotic Cardiovascular Disease

Cardiovascular·MeSH: Atherosclerosis

Prevalence

6000.0 / 100K

Incidence

500.0 / 100K/yr

16 drugs in development·9 companies·17 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
AZD0780	ASTRAZENECA PLC (AZN)
inclisiran sodium 300 mg in	Novartis AG (NVS)
inclisiran sodium 300 mg in	Novartis AG (NVS)
lepodisiran	ELI LILLY & Co (LLY)
Lepodisiran Sodium	ELI LILLY & Co (LLY)
Olpasiran	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
pelacarsen	Novartis AG (NVS)
tqj230	Novartis AG (NVS)

Phase 2(2)

Drug	Company
evolocumab	Novo Nordisk A/S (NVO)
nnc0385-0434 a	Novo Nordisk A/S (NVO)

Unknown(4)

Drug	Company
alirocumab	Sanofi (SNY)
alirocumab	Sanofi (SNYNF)
inclisiran	Sanofi (SNYNF)
inclisiran	Sanofi (SNY)

Phase 1/Phase 2(1)

Drug	Company
tb-500	IO Biotech, Inc. (IOBT)

Phase 4(1)

Drug	Company
Atozet 10/40 mg or 10/80 mg	Organon & Co. (OGN)

Compare drugs

AZD0780 vs inclisiran sodium 300 mg in AZD0780 vs lepodisiran AZD0780 vs Lepodisiran Sodium

Frequently asked questions

How many drugs are in development for Atherosclerotic Cardiovascular Disease?

BioSniper tracks 16 drugs in development for Atherosclerotic Cardiovascular Disease across 9 companies.

How many clinical trials target Atherosclerotic Cardiovascular Disease?

There are 17 clinical trials targeting Atherosclerotic Cardiovascular Disease tracked by BioSniper.

What is the prevalence of Atherosclerotic Cardiovascular Disease?

The estimated prevalence of Atherosclerotic Cardiovascular Disease is approximately 6000.0 per 100,000 population.

Deep-dive into Atherosclerotic Cardiovascular Disease

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Atherosclerotic Cardiovascular Disease — Drugs in Development & Clinical Trials | BioSniper